Literature DB >> 12756943

Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents.

Kenneth R Phares1, William E Weiser, Stephen P Miller, Melissa A Myers, Michael Wade.   

Abstract

The stability of treprostinil sodium after dilution in three common i.v. infusion vehicles was assessed. The chemical stability of treprostinil sodium was tested over a 48-hour period at 40 degrees C and 75% relative humidity after dilution in each of three diluents: sterile water for injection, 0.9% sodium chloride injection, and 5% dextrose injection, and after passage through an i.v. delivery system. Chemical analysis was conducted by using a validated stability-indicating high-performance liquid chromatographic assay, visually inspecting the solutions, and measuring the pH of each solution. The preservative effectiveness of the solutions was tested by the recovery of inoculations of compendial microorganisms after 48 hours in dilute solutions of treprostinil sodium. All assay results for treprostinil were within 90.0% to 110.0% of the prepared solutions diluted at 0.004 and 0.13 mg/mL treprostinil sodium in sterile water for injection and 0.9% sodium chloride injection. The assay results were the same for dilute treprostinil solutions in 5% dextrose injection at concentrations of 0.02 and 0.13 mg/mL. The pH values for these solutions remained within acceptable values of 6.0 to 7.2 for the stability study. No change in physical appearance or any visible particulate matter was observed. Approximately 70% of metacresol, the preservative, in the dilute treprostinil sodium solutions was removed before reaching the terminal end of the tubing. None of the dilute treprostinil sodium solutions supported microbial growth in the cassette reservoirs for the organisms considered. Treprostinil sodium 0.13 mg/mL solution in sterile water for injection, 0.9% sodium chloride for injection, and 5% dextrose for injection appeared to be stable after storage in controlled ambulatory drug-delivery systems for 48 hours at 40 degrees C and 75% relative humidity. Treprostinil sodium 0.004 mg/mL in sterile water and 0.9% sodium chloride for injection and 0.02 mg/mL in 5% dextrose injection was also stable under the same conditions. None of the solutions showed signs of microbial growth.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12756943     DOI: 10.1093/ajhp/60.9.916

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  5 in total

1.  Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension.

Authors:  D Dunbar Ivy; Michelle Calderbank; Brandie D Wagner; Susan Dolan; Ann-Christine Nyquist; Michael Wade; William M Nickels; Aimee K Doran
Journal:  Infect Control Hosp Epidemiol       Date:  2009-09       Impact factor: 3.254

2.  Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension.

Authors:  A K Doran; D D Ivy; R J Barst; N Hill; S Murali; R L Benza
Journal:  Int J Clin Pract Suppl       Date:  2008-07

3.  BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension.

Authors:  Leslie A Spikes; Abubakr A Bajwa; Charles D Burger; Sapna V Desai; Michael S Eggert; Karim A El-Kersh; Micah R Fisher; Shilpa Johri; Joanna M Joly; Jinesh Mehta; Harold I Palevsky; Gautam V Ramani; Ricardo Restrepo-Jaramillo; Sandeep Sahay; Trushil G Shah; Chunqin Deng; Melissa Miceli; Peter Smith; Shelley M Shapiro
Journal:  Pulm Circ       Date:  2022-04-07       Impact factor: 2.886

4.  Successful management of an inadvertent excessive treprostinil overdose.

Authors:  Wolfgang Hohenforst-Schmidt; Juergen Hornig; Norbert Friedel; Paul Zarogoulidis; Konstantinos Zarogoulidis; Johannes Brachmann
Journal:  Drug Des Devel Ther       Date:  2013-03-21       Impact factor: 4.162

Review 5.  Treprostinil for pulmonary hypertension.

Authors:  Nika Skoro-Sajer; Irene Lang; Robert Naeije
Journal:  Vasc Health Risk Manag       Date:  2008
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.